Economic burden of respiratory syncytial virus disease in Latin America: A systematic review

C Moreno, A Bardach, MC Palermo… - Human vaccines & …, 2024 - Taylor & Francis
ABSTRACT This Systematic Review assesses the economic impact of Respiratory Syncytial
Virus (RSV) in Latin America and the Caribbean (LAC) in relation to healthcare resource …

National trends in prescription drug expenditures and projections for 2022

EM Tichy, JM Hoffman, KJ Suda, MH Rim… - American Journal of …, 2022 - academic.oup.com
Purpose To report historical patterns of pharmaceutical expenditures, to identify factors that
may influence future spending, and to predict growth in drug spending in 2022 in the United …

Cost-effectiveness of prefusion F protein-based vaccines against respiratory syncytial virus disease for older adults in the United States

SM Moghadas, A Shoukat, CE Bawden… - Clinical Infectious …, 2024 - academic.oup.com
Background Two prefusion F protein-based vaccines, Arexvy and Abrysvo, have been
authorized by the US Food and Drug Administration for protecting older adults against …

Acute Cardiac Events in Hospitalized Older Adults With Respiratory Syncytial Virus Infection

RC Woodruff, M Melgar, H Pham… - JAMA Internal …, 2024 - jamanetwork.com
Importance Respiratory syncytial virus (RSV) infection can cause severe respiratory illness
in older adults. Less is known about the cardiac complications of RSV disease compared …

Burden of Acute Respiratory Infections Caused by Influenza Virus, Respiratory Syncytial Virus, and SARS-CoV-2 with Consideration of Older Adults: A Narrative …

WP Hanage, W Schaffner - Infectious Diseases and Therapy, 2024 - Springer
Influenza virus, respiratory syncytial virus (RSV), and severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) are acute respiratory infections (ARIs) that can cause …

Hospitalizations due to respiratory syncytial virus (RSV) infections in Germany: a nationwide clinical and direct cost data analysis (2010–2019)

P Niekler, D Goettler, JG Liese, A Streng - Infection, 2023 - Springer
Purpose Clinical and direct medical cost data on RSV-related hospitalizations are relevant
for public health decision-making. We analyzed nationwide data on RSV-coded …

Randomized, open-label phase 3 study evaluating immunogenicity, safety, and reactogenicity of RSVPreF3 OA coadministered with FLU-QIV-HD in adults aged≥ 65

R Buynak, K Cannon, D DeAtkine, J Kirby… - Infectious Diseases and …, 2024 - Springer
Introduction Respiratory syncytial virus (RSV) and influenza pose major disease burdens in
older adults due to an aging immune system and comorbidities; seasonal overlap exists …

Comment on Postma et al. Predicted Public Health and Economic Impact of Respiratory Syncytial Virus Vaccination with Variable Duration of Protection for Adults≥ …

B Standaert - Vaccines, 2023 - mdpi.com
Vaccines | Free Full-Text | Comment on Postma et al. Predicted Public Health and Economic
Impact of Respiratory Syncytial Virus Vaccination with Variable Duration of Protection for Adults …

An Overview on Disease Burden and Management of Respiratory Syncytial Virus Infections in Older Adults in the Asia‐Pacific Region

CC Lai, PR Hsueh - Reviews in Medical Virology, 2024 - Wiley Online Library
Respiratory syncytial virus (RSV) represents a significant burden on older adults (aged≥ 50
years) globally and can lead to acute respiratory tract infections with substantial morbidity …

[HTML][HTML] Polyoxometalate exerts broad-spectrum activity against human respiratory viruses hampering viral entry

I Arduino, R Francese, A Civra, E Feyles… - Antiviral Research, 2024 - Elsevier
Human respiratory viruses have an enormous impact on national health systems, societies,
and economy due to the rapid airborne transmission and epidemic spread of such …